What Are Degrader-Antibody Conjugates (DACs)? Next-Generation ADC Technology and the Global Pipeline Landscape
The excitement surrounding antibody-drug conjugates (ADCs) has not yet faded, but a new frontier is…
Articles
The World’s Second CFB Inhibitor Lanoracopan Approved by NMPA: China-Developed PNH Therapy Marks a Breakthrough
On June 11, China’s National Medical Products Administration (NMPA) officially approved Wuhan Createrna Science and…
Gumokimab Approved for Plaque Psoriasis in China: The IL-17A Therapy Landscape Continues to Evolve
On June 11, Akeso announced that its self-developed IL-17A monoclonal antibody, Gumokimab (AK111, brand name…
New Hemophilia Drug Approved in China: Bemiltenase Alfa Becomes World’s First Factor X Activator
On June 4, 2026, the NMPA officially announced that injectable Bemiltenase alfa (Goxblem), a Class…
Access Pathways for Innovative Medicines in China: Hospitals, Pharmacies, and Pharmaceutical Distribution Channels
More and more overseas patients are beginning to explore China’s innovative drug resources in search…
May 2026 China Innovative Drug Approvals: 5 Major New Drugs Approved
China’s innovative drug industry continues to achieve major breakthroughs. According to public information released by…
Which Cancers Does China Have Advantages In? Top 5 Areas of Strength Explained
From precision medicine to immunotherapy, from novel targeted drugs to cell therapy, China has formed…
Causes of the Global Counterfeit Drug Problem and Safe Pharmaceutical Procurement Guide
In today’s increasingly complex pharmaceutical distribution system and highly active cross-border trade environment, counterfeit medicines…
China Peptide API Company Landscape and Capacity Distribution
As Semaglutide, Tirzepatide, and next-generation multi-target peptides like Retatrutide advance in development and commercialization, China’s…
Nipocalimab Approved in China for Generalized Myasthenia Gravis, With Long-Term Stable Disease Control Emerging as a Key Highlight
On May 21, Johnson & Johnson announced that its FcRn antagonist Imaavy® (nipocalimab injection) received…